...
首页> 外文期刊>Allergy >Short-term prophylactic treatment of hereditary angioedema with icatibant.
【24h】

Short-term prophylactic treatment of hereditary angioedema with icatibant.

机译:依卡替班短期预防性治疗遗传性血管性水肿。

获取原文
获取原文并翻译 | 示例
           

摘要

Hereditary type 1 angioedema (HAE) due to quantitative deficiency of Cl-esterase inhibitor (Cl-INH) is a bradykinin- dependent dis- ease that can be treated with icatibant (Jerini, Berlin), a novel bradykinin B2-receptor antagonist (1). Patients with HAE can suffer bouts of angioedema with surgical or invasive medical procedures. In such cases a short-prophylactic treatment has to be considered (2, 3). There is no approved medication for this indication in Spain. Until now, patients in this situation were treated with intravenously administered Cl-INH concentrate derived from human plasma.
机译:由于Cl酯酶抑制剂(Cl-INH)的定量缺乏而导致的遗传性1型血管性水肿(HAE)是一种缓激肽依赖性疾病,可以用新型缓激肽B2受体拮抗剂icatibant(Jerini,Berlin)治疗(1 )。 HAE患者可通过外科或侵入性医疗程序患上血管性水肿。在这种情况下,必须考虑采取短期预防措施(2、3)。西班牙目前没有批准的药物可用于这种适应症。到目前为止,这种情况下的患者都接受了静脉注射源自人血浆的Cl-INH浓缩物的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号